Hematopoiesis News 9.34 August 28, 2018 | |
| |
TOP STORYResearchers showed that SIRT1 protein levels were downregulated in myelodysplastic syndrome (MDS) hematopoietic stem/progenitor cells. Genetic or pharmacological activation of SIRT1 inhibited MDS HSPC functions, whereas SIRT1 deficiency enhanced MDS HSPC self-renewal. [Cell Stem Cell] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Pathobiologic Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes The authors showed that hypoxia-independent activation of hypoxia-inducible factor 1α signaling is both necessary and sufficient to induce dysplastic and cytopenic myelodysplastic syndrome phenotypes. [Cancer Discov] Abstract | Press Release JMJD3 Facilitates C/EBPβ-Centered Transcriptional Program to Exert Oncorepressor Activity in AML Researchers showed that in contrast to its oncogenic effect in preleukemia state and lymphoid malignancies, JMJD3 relieved the differentiation-arrest of certain subtypes of acute myeloid leukemia (AML) cells. [Nat Commun] Full Article Screening for Genes that Regulate the Differentiation of Human Megakaryocytic Lineage Cells The authors utilized screening approaches to study the transcriptional regulators of megakaryocyte progenitor generation, a key step before platelet production. Promising candidate genes were generated from a microarray platform gene expression commons and individually manipulated in human hematopoietic stem and progenitor cells. [Proc Natl Acad Sci USA] Abstract Specific Oxylipins Enhance Vertebrate Hematopoiesis via the Receptor GPR132 Knockdown of zebrafish gpr132b prevented epoxyeicosatrienoic acid-induced hematopoiesis, and marrow from GPR132 knockout mice showed decreased long-term engraftment capability. [Proc Natl Acad Sci USA] Abstract Using a CD82 knock out mouse model, the authors determined that CD82 modulates hematopoietic stem and progenitor cell bone marrow maintenance, homing and engraftment. [Mol Biol Cell] Abstract | Full Article Researchers indicated that unconditioned NRG and NRGS mice could harbor established AML cell line-derived xenograft (CDX), and could tolerate aggressive induction chemotherapy at higher doses than NSG mice without overt toxicity. However, unconditioned NRGS mice developed less clinically relevant disease with CDXs forming solid tumors throughout the body, while unconditioned NRG mice were incapable of efficiently supporting PDX or human hematopoietic stem cell engraftment. [Exp Hematol] Abstract CLINICAL RESEARCHThe authors found that the absolute NKG2A+ subset cell counts and the percentages of NKG2A+ among natural killer (NK) cells were significantly reduced in graft-versus-host disease (GvHD) patients after allogeneic stem cell transplantation compared to those from non-GvHD patients. [Biol Blood Marrow Transplant] Abstract Investigators treated 15 men who had developed adult cerebral form of X-linked adrenoleukodystrophy with allogeneic haematopoietic stem cell transplantation from matched donors after myeloablative conditioning with busulfan and cyclophosphamide. [J Inherit Metab Dis] Abstract Scientists investigated the relevance of miRNAs in exosomes derived from patients developing late-onset acute graft-versus-host disease (LA GvHD) after allogeneic hematopoietic stem cell transplantation. Plasma samples were collected from patients with LA GVHD, non-GVHD, and controls for exosomal miRNA expression profiling using a TaqMan low-density array. [Int J Mol Sci] Full Article Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News. | |
| |
REVIEWSDelivering Hematopoietic Stem Cell Gene Therapy Treatments for Neurological Lysosomal Diseases Ex vivo gene therapy approaches to overexpress the missing enzyme in hematopoietic stem cells prior to transplant are an emerging technology that has the potential to offer a viable therapy for patients. [ACS Chem Neurosci] Full Article Advances in the Gene Therapy of Fanconi Anemia Due to the rapid progression in the field of gene editing, recent studies have shown the feasibility of correcting CD34+ cells from fanconi anemia (FA) patients using gene targeting strategies. Taken together, all these advances suggest that gene therapy will soon be used as an efficient and safe alternative for the hematopoietic treatment of patients with FA. [Hum Gene Ther] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
INDUSTRY NEWSOmeros Corporation announced that the European Commission has adopted a decision designating OMS721 as an Orphan Medicinal Product in the European Union for treatment in hematopoietic stem cell transplantation. [Omeros Corporation] Press Release Jazz Pharmaceuticals plc announced that the European Commission approved Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. [Jazz Pharmaceuticals plc (PR Newswire Association, LLC.)] Press Release uniQure N.V. announced that it has treated the first patient in its Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy incorporating the FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. [uniQure N.V.] Press Release Bristol-Myers Squibb Company announced that the FDA accepted its supplemental Biologics License Application for Empliciti in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. [Bristol-Myers Squibb Company] Press Release Global Blood Therapeutics, Inc. announced that it has entered into an exclusive worldwide licensing agreement with F. Hoffmann-La Roche Ltd. for the development and commercialization of inclacumab, a novel fully human monoclonal antibody against P-selectin. [Global Blood Therapeutics, Inc.] Press Release | |
| |
POLICY NEWSNIH Investigating Whether U.S. Scientists Are Sharing Ideas with Foreign Governments Fears that foreign governments are tapping U.S.-funded research for valuable information have reached the nation’s largest research funder, the National Institutes of Health (NIH) in Bethesda, Maryland. It sent a letter to more than 10,000 research institutions, urging them to ensure that NIH grantees are properly reporting their foreign ties. [ScienceInsider] Editorial US Senate Passes Spending Bill Granting NIH $39.1 Billion The US Senate passed a spending bill allotting $39.1 billion to the National Institutes of Health (NIH) for the 2019 fiscal year starting on October 1. [The Scientist] Editorial India Targets Universities in Predatory-Journal Crackdown Most academics regard predatory journals as an irritant – if not a threat – to science. But in India, some universities have recommended the inclusion of such publications in the country’s ‘white list’ of approved journals. Now the government is cracking down on this practice, which scientists say came about as a result of perverse government incentives. [Nature News] Editorial
| |
EVENTSNEW Blood 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Senior Scientist – CAR T-Cell Research (CELLECTIS Inc.) Faculty Position – Hematopathologist (St. Jude Children’s Research Hospital) Postdoctoral Researcher – Molecular Hematology (Lund University) Postdoctoral Fellow – Aging of Hematopoietic Stem Cells (City of Hope) Research Technicians – Hematopoiesis (Fred Hutchinson Cancer Research Center) Postdoctoral Research Fellow – Hematopoiesis (Fred Hutchinson Cancer Research Center) Endowed Chair – Cancer Research (University of Iowa Health Care) Career Development Program – Glycoscience (BloodCenter of Wisconsin) Postdoctoral Researcher – Regulation of Normal and Malignant Hematopoiesis (Karolinska Institutet) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|